EGFR and non-small cell lung carcinoma: Among NSCLC patients with co-occurring potentially oncogenic drivers, 80% (37/46) harbored EGFR mutations and other concurrent potentially targetable drivers, commonly involving de novo MET amplifications (21.6%; 8/37) and alterations in ERBB2 including mutations (27.0%; 10/37) and amplification (21.6%; 8/37).